{
    "clinical_study": {
        "@rank": "142989", 
        "arm_group": {
            "arm_group_label": "Nimotuzumab", 
            "arm_group_type": "Experimental", 
            "description": "the nimotuzumab treatment: 2 levels (400 mg/w, 600 mg/w, weekly, until disease progression)"
        }, 
        "brief_summary": {
            "textblock": "Nimotuzumab is an IgG1 humanized monoclonal antibody that recognized an epitope located in\n      the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical\n      efficacy has been shown in adult with head and neck cancer. The study assessed the safety\n      and efficacy of different dosage of Nimotuzumab in second  or late- line treatment of\n      patients with locally advanced or metastatic esophageal squamous cell carcinomas."
        }, 
        "brief_title": "Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Esophageal Squamous Cell Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Neoplasms, Squamous Cell"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed esophageal squamous carcinoma,failed to first or second line\n             chemothrepay\n\n          -  Age 18 to 75 years old\n\n          -  Measurable disease according to the RECIST criteria(diameter of the lesion should be\n             more than 10mm by spiral CT or MRI, more than 20mm by common CT, the date of image\n             should be less than 15 days before enrollment)\n\n          -  Life expectancy of \u22653 month\n\n          -  Karnofsky performance status \u226580\n\n          -  WBC>3,000/mm3, absolute neutrophil count \u22651500/mm3, platelet>100,000/mm3,\n             Hb>9g/dl\uff0cBilirubin level < 1.0 times ULN\uff0cSerum creatinine <1.0 times ULN\uff0cALT and\n             AST<2.5 times ULN \uff0cAKP < 2.5 times ULN \uff0c(\u22645 times ULN in patients with liver\n             metastases)(within 7 days before enrollment)\n\n          -  No sever complication, such as active gastrointestinal bleeding, perforation,\n             jaundice, obstruction, non-cancerous fever\uff1e38\u2103\uff1b\n\n          -  Normal ECG/cardiac function\n\n          -  Good compliance\n\n          -  Having signed informed consent -\n\n        Exclusion Criteria:\n\n          -  No previous systemic therapy for metastatic esophageal squamous carcinoma\n\n          -  Known hypersensitivity to study drugs\n\n          -  Tumor with length\u226510cm, liver metastasis covers more than 50% of liver,or lung\n             metastasis covers more than 25% of lung\n\n          -  No measurable lesions, eg. pleural fluid and ascites\n\n          -  Only with Other previous malignancy within 5 year, except non-melanoma skin cancer\n\n          -  Heart failure or other sever organ dysfunction, eg. coronary artery disease,\n             myocardial infarction within the last 6 months only Brain or bone metastasis\n\n          -  Chronic diarrhea\n\n          -  Mentally abnormal or disable cognition,including CNS metastasis\n\n          -  Pregnancy or lactation period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 16, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993784", 
            "org_study_id": "ESCC-N-301"
        }, 
        "intervention": {
            "arm_group_label": "Nimotuzumab", 
            "intervention_name": "nimotuzumab", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "contact": {
                "email": "lin100@medmail.com.cn", 
                "last_name": "Lin Shen, MD", 
                "phone": "+86-10-88196561"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100142"
                }, 
                "name": "Peking University Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "Lin Shen", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase IIa Study of Nimotuzumab in Second or Late- Line Treatment of Patients With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinomas", 
        "overall_contact": {
            "email": "pppeirain@126.com", 
            "last_name": "Zhihao Lu, MD", 
            "phone": "86-10-88196561"
        }, 
        "overall_contact_backup": {
            "email": "lin100@medmail.com.cn", 
            "last_name": "Lin Shen, MD", 
            "phone": "86-10-88196561"
        }, 
        "overall_official": {
            "affiliation": "Peking Universtiy Cancer Hospital", 
            "last_name": "Lin Shen, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "CT/MRI will be performed every 2 cycles of treatment for efficacy evaluation", 
            "measure": "Objective response rate", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993784"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University", 
            "investigator_full_name": "Shen Lin", 
            "investigator_title": "Department of GI Oncology,Peking University, School of Oncology, Beijing Cancer Hospital & Institute", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "participants will be followed for the duration of hospital stay, an expected average of 1 week", 
            "measure": "adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "during the treatment in the hosptital,an expected average of 1 week"
        }, 
        "source": "Peking University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}